lunes, 23 de noviembre de 2015

AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting. - PubMed - NCBI

AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting. - PubMed - NCBI



 2015 Nov 3;782:44-51. doi: 10.1016/j.mrfmmm.2015.10.005. [Epub ahead of print]

AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting.

Abstract

The American Association for Cancer Research (AACR) Precision Medicine Series "Integrating Clinical Genomics and Cancer Therapy" took place June 13-16, 2015 in Salt Lake City, Utah. The conference was co-chaired by Charles L. Sawyers form Memorial Sloan Kettering Cancer Center in New York, Elaine R. Mardis form Washington University School of Medicine in St. Louis, and Arul M. Chinnaiyan from University of Michigan in Ann Arbor. About 500 clinicians, basic science investigators, bioinformaticians, and postdoctoral fellows joined together to discuss the current state of Clinical Genomics and the advances and challenges of integrating Next Generation Sequencing (NGS) technologies into clinical practice. The plenary sessions and panel discussions covered current platforms and sequencing approaches adopted for NGS assays of cancer genome at several national and international institutions, different approaches used to map and classify targetable sequence variants, and how information acquired with the sequencing of the cancer genome is used to guide treatment options. While challenges still exist from a technological perspective, it emerged that there exists considerable need for the development of tools to aid the identification of the therapy most suitable based on the mutational profile of the somatic cancer genome. The process to match patients to ongoing clinical trials is still complex. In addition, the need for centralized data repositories, preferably linked to well annotated clinical records, that aid sharing of sequencing information is central to begin understanding the contribution of variants of unknown significance to tumor etiology and response to therapy. Here we summarize the highlights of this stimulating four-day conference with a major emphasis on the open problems that the clinical genomics community is currently facing and the tools most needed for advancing this field.
Copyright © 2015. Published by Elsevier B.V. All rights reserved.

KEYWORDS:

American Association for Cancer Research; Biomarkers; Meeting; Personal genomics; Personalized medicine; Precision medicine; Target sequencing; Target therapy; Whole exome sequencing

PMID:
 
26554403
 
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario